Anti-hepatoma Effect of DC2.4 Cells Transfected with Tumor-Associated Antigen Cdc25C In Vitro

Abstract

Objective

Cell division cyclin 25 homolog C (Cdc25C) is a tumor-associated antigen candidate gene, and this may be used as an effective target in cancer treatment. The present study aims to evaluate the lysis effect of cytotoxic T lymphocytes (CTLs) induced by dendritic cell line DC2.4 overexpressing Cdc25C, and the feasibility of Cdc25C as a component in hepatoma immunotherapy.

Methods

The mouse Cdc25C gene was ligated into a lentiviral vector, and transfected into DC2.4 cells. The DC2.4 cell phenotype and cytokine secretion were determined by flow cytometry and ELISA, respectively. CD8⁺ T cells were sorted from the spleens of C57BL/6 mice using a magnetic bead sorting kit obtained from Miltenyi Biotech, Germany, and co-cultured with DC2.4 cells for one week as effector cells. Then, IL-2, granzyme B and perforin were detected in the CTL culture medium by ELISA. Next, time-resolved fluorescence immunoassay was used to detect the immune killing effect of Cdc25C-specific CTLs on target cells. Meanwhile, the effect of blocking MHC-I sites on target cells with a monoclonal anti-MHC-I antibody was evaluated.

Results

The results revealed that Cdc25C could be stably overexpressed in DC2.4 cells by LV-Cdc25C infection. DC2.4 cells transfected with LV-Cdc25C secreted more IL-6, IL-12, TNF-α and IFN-γ, and had higher expression levels of CD40, CD86, CCR7 and MHC-II than unaltered DC2.4 cells. The elevated Cdc25C in dendritic cells also further increased the secretion of IL-2, granzyme B and perforin to elicit Cdc25C-specific CTLs, and induced the higher cytotoxicity in Hepa1-6 cell lines (P<0.05), but this had no effect on the target cells when MHC-I monoclonal antibodies were blocked.

Conclusion

DC2.4 cells transfected with LV-Cdc25C can induce specific CTLs, and result in a strong cellular immune response. The dendritic cells that overexpress Cdc25C may be useful for hepatoma immunotherapy.

Keywords

dendritic cells / cell division cyclin 25 homolog C / cytotoxic T lymphocytes / hepatocellular carcinoma / anti-hepatoma

References

[1] JessusC, OzonR. Function and regulation of cdc25 protein phosphate through mitosis and meiosis. Prog Cell Cycle Res, 1995, 1: 215-228

[2] SurS, AgrawalDK. Phosphatases and kinases regulating CDC25 activity in the cell cycle: clinical implications of CDC25 overexpression and potential treatment strategies. Mol Cell Biochem, 2016, 416(1–2): 33-46

[3] KristjánsdóttirK, RudolphJ. Cdc25 phosphatases and cancer. Chem Biol, 2004, 11(8): 1043-1051

[4] KawabeT. G2 checkpoint abrogators as anticancer drugs. Mol Cancer Ther, 2004, 3(4): 513-519

[5] WangJ, ChangL, LaiX, et al.. Tetrandrine enhances radiosensitivity through the CDC25C/CDK1/cyclin B1 pathway in nasopharyngeal carcinoma cells. Cell Cycle, 2018, 17(6): 671-680

[6] WangX, ZhaoH, XuQ, et al.. HPtaa database-potential target genes for clinical diagnosis and immunotherapy of human carcinoma. Nucleic Acids Res, 2006, 34: D607-612

[7] BryantCE, SutherlandS, KongB, et al.. Dendritic cells as cancer therapeutics. Semin Cell Dev Biol, 2019, 86: 77-88

[8] KimTS, GorskiSA, HahnS, et al.. Distinct dendritic cell subsets dictate the fate decision between effector and memory CD8(+) T cell differentiation by a CD24-dependent mechanism. Immunity, 2014, 40(3): 400-413

[9] SchietingerA, PhilipM, KrisnawanVE, et al.. Tumor-specific T cell dysfunction is a dynamic antigen-driven differentiation program initiated early during tumorigenesis. Immunity, 2016, 45(2): 389-401

[10] FuC, JiangA. Dendritic Cells and CD8 T Cell Immunity in Tumor Microenvironment. Front Immunol, 2018, 9: 3059

[11] MünzC, SteinmanRM, FujiiS. Dendritic cell maturation by innate lymphocytes: coordinated stimulation of innate and adaptive immunity. J Exp Med, 2005, 202(2): 203-207

[12] HopkinsRA, ConnollyJE. The specialized roles of immature and mature dendritic cells in antigen cross-presentation. Immunol Res, 2012, 53(1–3): 91-107

[13] de VriesIJ, LesterhuisWJ, ScharenborgNM, et al.. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res, 2003, 9(14): 5091-5100

[14] LanzavecchiaA, SallustoF. Regulation of T cell immunity by dendritic cells. Cell, 2001, 106(3): 263-266

[15] EvertsB, TussiwandR, DreesenL, et al.. Migratory CD103+ dendritic cells suppress helminth-driven type 2 immunity through constitutive expression of IL-12. J Exp Med, 2016, 213(1): 35-51

[16] MaraskovskyE, ChenWF, ShortmanK. IL-2 and IFN-gamma are two necessary lymphokines in the development of cytolytic T cells. J Immunol, 1989, 43(4): 1210-1214

[17] RudraJS, BanasikBN, MilliganGN. A combined carrier-adjuvant system of peptide nanofibers and tolllike receptor agonists potentiates robust CD8⁺ T cell responses. Vaccine, 2018, 36(4): 438-441

[18] TanPH, BeutelspacherSC, XueSA, et al.. Modulation of human dendritic-cell function following transduction with viral vectors: implications for gene therapy. Blood, 2005, 105(10): 3824-3832

[19] FelizardoTC, WangJC, McGrayRA, et al.. Differential immune responses mediated by adenovirus- and lentivirus-transduced DCs in a HER-2/neu overexpressing tumor model. Gene Ther, 2011, 18(10): 986-995

[20] WangJC, FelizardoTC, AuBC, et al.. Engineering lentiviral vectors for modulation of dendritic cell apoptotic pathways. Virol J, 2013, 10: 240

[21] BrozML, BinnewiesM, BoldajipourB, et al.. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer cell, 2014, 26(5): 638-652

[22] SalmonH, IdoyagaJ, RahmanA, et al.. Expansion and activation of CD103(+) dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition. Immunity, 2016, 44(4): 924-938

[23] SaeidiA, BuggertM, CheKF, et al.. Regulation of CD8+ T-cell cytotoxicity in HIV-1 infection. Cell Immunol, 2015, 298(1–2): 126-133

[24] JangJE, HajduCH, LiotC, et al.. Crosstalk between regulatory T cells and tumor-associated dendritic cells negates anti-tumor immunity in pancreatic cancer. Cell Rep, 2017, 20(3): 558-571

[25] ChamotoK, KosakaA, TsujiT, et al.. Critical role of the Th1/Tc1 circuit for the generation of tumor-specific CTL during tumor eradication in vivo by Th1-cell therapy. Cancer Sci, 2003, 94(10): 924-928

[26] AccollaRS, RamiaE, TedeschiA, et al.. CIITA-Driven MHC Class II Expressing Tumor Cells as Antigen Presenting Cell Performers: Toward the Construction of an Optimal Anti-tumor Vaccine. Front Immunol, 2019, 10: 1806